Jefferies Boosts Olema Oncology Price Target on Strong SERD Momentum
Jefferies raises Olema Oncology’s price target to $43 as new Roche giredestrant data strengthens confidence in next-generation SERDs and multibillion-dollar market potential.
/ 3 items
#OLMA↓
Roche's Giredestrant Success: Cutting Breast Cancer Recurrence Risk
Roche’s experimental SERD, giredestrant, showed unprecedented success in a late-stage trial, cutting recurrence risk in early-stage, ER-positive breast cancer.
Olema Stock Crashes on Roche's Shadow, Not Its Own Data
Despite positive palazestrant (OP-1250) trial results, Olema Pharmaceuticals' shares dropped Monday, overshadowed by disappointing outcomes from a Roche breast cancer study.